Abstracts tagged "Patient reported outcomes"

Abstract Number: 1458 • ACR Convergence 2022
Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment
Delansie Lawrence¹, Jiandong Su¹, Andrea Knight², Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, Joan Wither⁶, May Choi⁷, Simone Appenzeller⁸, Nicole Anderson¹, Dennisse Bonilla¹, Patricia Katz⁹, Dorcas Beaton¹⁰, Robin Green⁵, Zahi Touma¹ and Michelle Barraclough¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, São Paulo, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with systemic lupus erythematosus (SLE). Objective prevalence rates are reported as 38% [range: 20% to 80%]…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: PP07 • ACR Convergence 2022
Remissions and Vigilance
Michael Scepaniak, Cockeysville, MD
Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…
Abstract Number: 0192 • ACR Convergence 2022
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Laura Coates¹, Arthur Kavanaugh², Erin McDearmon-Blondell³, Arthur Mandelin⁴, Tianming Gao⁵ and William Tillett⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²University of California San Diego, La Jolla, CA, ³AbbVie, Inc., Mettawa, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵AbbVie, Inc., North Chicago, IL, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index calculated from 3 patient-reported measures: physical function, pain, and patient global…
Abstract Number: 0344 • ACR Convergence 2022
Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie Bartels⁴, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Lupus, the leading cause of chronic kidney disease (CKD) in young women, is treated with Hydroxychloroquine (HCQ) which is primarily excreted by kidneys. Yet…
Abstract Number: 0523 • ACR Convergence 2022
The Development of the Ranked Composite Important Difference in Diffuse Cutaneous Systemic Sclerosis; A Clinical and Patient Meaningful Anchor to the ACR-Composite Response Index in SSc
Lesley-Anne Bissell¹, Daniel Furst², sindhu johnson³, Paul hansen⁴, Esmeralda Recalde⁵, Dinesh Khanna⁶ and Francesco Del Galdo⁷, ¹University of Leeds, Leeds, United Kingdom, ²University of California Los Angeles, Los Angeles, CA, ³Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Otago, Dunedin, New Zealand, ⁵World Scleroderma Foundation, Florence, Italy, ⁶Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: The ACR Composite Response Index in Systemic Sclerosis ( ACR-CRISS) is one of the first composite outcome measures in diffuse cutaneous Systemic sclerosis (dcSSc-…
Abstract Number: 0901 • ACR Convergence 2022
Factors Associated with Household Work Limitations in Mexican Patients with Rheumatoid Arthritis: The Impact of the Disease on Women’s Life
Ana Ortiz-Haro¹, Irazu Contreras-Yáñez¹, Guillermo Guaracha Basañez² and Virginia Pascual Ramos³, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is the most frequent chronic inflammatory arthritis with a clear female preponderance. For various reasons, women spend more time on household…
Abstract Number: 1340 • ACR Convergence 2022
Nutrition-Related Behaviors and Beliefs – A Survey of Rheumatic Disease Patients
Sandy Lee¹, Leanna Wise² and Stavros Savvas³, ¹University of Southern California, Walnut, CA, ²LAC+USC/Keck Medicine of USC, Pasadena, CA, ³Keck Medicine of USC, Glendale, CA
Background/Purpose: Diet and nutrition have long been of interest to both patients and providers in the treatment of chronic disease. The literature is relatively sparse…
Abstract Number: 1470 • ACR Convergence 2022
Work Disability and Function in Systematic Lupus Erythematosus (SLE): Results from a Mixed-Methods Exploratory Canadian Study
Behdin Nowrouzi-Kia¹, J. Antonio Avina-Zubieta², Mary T Fox³, William Shaw⁴, Maggie Ho⁵, Derek Haaland⁶, Janet Pope⁷, Paul R Fortin⁸, Kathleen Bingham⁹, Nathalie Rozenbojm¹⁰, Mark Matsos¹¹, Christine Peschken¹², Amanda Steiman¹³, Earl Silverman¹⁴, Jiandong Su¹⁵, Jennifer Reynolds¹⁶, Catherine Ivory¹⁷, Dafna Gladman¹⁸, Murray Urowitz¹⁹, Francisco Sanchez-Guerrero²⁰, Lily Lim¹², Stephanie Keeling²¹, Ana Soberanis¹, Patricia Katz²² and Zahi Touma¹⁵, ¹University of Toronto, Toronto, ON, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³York University, Toronto, ON, Canada, ⁴University of Connecticut School of Medicine, Framington, CT, ⁵University Health Network, Toronto Western Hospital, Toronto, ON, Canada, ⁶The Waterside Clinic, Oro Medonte, ON, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ⁹Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ¹⁰University Health Network, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³Sinai Health System, Toronto, ON, Canada, ¹⁴The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ¹⁶University of British Columbia Dept of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ¹⁷University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ¹⁸Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁹University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ²⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ²¹University of Alberta, Edmonton, AB, Canada, ²²UCSF, San Rafael, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystemic, autoimmune disease which can result in disability and mortality. A functional assessment tool that measures the…
Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹Stanford University School of Medicine, Stanford, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
Abstract Number: PP12 • ACR Convergence 2022
We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board
Zucy Almonacid¹, Wigna Cruz², Francisca Garcia³, Teresa Hernandez⁴, Velia Martinez⁵, Patricia Mattos³, Mario Mutis⁶ and Denise Serrano⁷, ¹Hicsville, NY, ²Juan Diaz, PR, ³Lake Worth, FL, ⁴Greenacres, FL, ⁵Guaynabo, PR, ⁶Fort Pierce, FL, ⁷Toa Alto, PR
Background/Purpose: Each of us has been diagnosed with rheumatoid arthritis (RA), from as recently as one year ago to as long as 20 years ago.…
Abstract Number: 0193 • ACR Convergence 2022
Factors Influencing Visit Preference in Patients with Rheumatic Diseases: A Qualitative Study
Kiara Aaron¹, Catherine Nasrallah², Lesley Jackson¹, Sarah Goglin³, Diana Paez⁴, David Chae⁵, Faith Mugeta¹, Norma Techarukpong¹, Ellen McNeeley¹, Gary Cutter¹, kenneth saag¹, Mary Margaretten⁴ and Maria Danila¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²UCSF, San Francisco, ³University of California San Francisco, San Francisco, CA, ⁴University of California San Francisco, San Francisco, ⁵Tulane University School of Public Health and Tropical Medicine, New Orleans, LA
Background/Purpose: The COVID-19 pandemic has increased the use of telemedicine visits for patients living with rheumatic and musculoskeletal diseases (RMD). The factors that influence preferences…
Abstract Number: 0347 • ACR Convergence 2022
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Christopher Bell¹, Bernie Rubin², Karen Worley³, Guillaume Germain⁴, François Laliberté⁴, Sean D. MacKnight⁴, Ana Urosevic⁴ and Mei Sheng Duh⁵, ¹GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ³GlaxoSmithKline, US Value, Evidence and Outcomes, Cincinnati, OH, ⁴Groupe d’analyse, Montréal, QC, Canada, ⁵Analysis Group Inc, Boston, MA
Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…
Abstract Number: 0572 • ACR Convergence 2022
ACR Workgroup to Develop Recommendations for PRO Use in Clinical Care for SLE
Patricia Katz¹, Claire Barber², Ali Duarte-Garcia³, Shivani Garg⁴, Wambui Machua⁵, Yesenia Santiago-Casas⁶, Wendy Rodgers⁷, Lisa Suter⁸, Jennifer Ude⁹, Tracy Johansson⁹, Christie Bartels¹⁰ and Jinoos Yazdany¹¹, ¹UCSF, San Rafael, CA, ²University of Calgary, Calgary, AB, Canada, ³Mayo Clinic, Rochester, MN, ⁴University of Madison, School of Medicine and Public Health, Madison, WI, ⁵Piedmont Physicians, Rheumatology, Atlanta, GA, ⁶Integral Rheumatology and Immunology Specialists, Plantation, FL, ⁷Lupus Foundation of America, Torrance, CA, ⁸Yale School of Medicine, New Haven, CT, ⁹American College of Rheumatology, Atlanta, GA, ¹⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹¹UCSF, San Francisco, CA
Background/Purpose: Patient-reported outcome (PRO) measures are not consistently used in clinical settings for patients with systemic lupus erythematosus (SLE). As part of a Centers for…
Abstract Number: 0912 • ACR Convergence 2022
Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis
Kristin Wipfler¹, Joanna Zeiger², Teresa Simon³, Stuart Kassan⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁴Colorado Arthritis Associates, Lakewood, CO, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Fatty acid amide hydrolase (FAAH) is a serine hydrolase that breaks down the endocannabinoid/cannabinoid receptor agonist anandamide. Variants in the FAAH gene have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].